The next GLP1 revolution: why Novo Nordisk and Eli Lilly want to replace weekly injections with pills

Every era of medicine has a defining object. For the GLP1 era, it has been the pen — a small, weekly injection device tucked into bathroom drawers and handbags from Los Angeles to London, quietly rewriting how millions of people experience hunger. Wegovy, Ozempic, Mounjaro, Zepbound: all of them, until now, are stories you tell with a needle.

That is about to change. Inside the research divisions of Novo Nordisk and Eli Lilly, and in clinical trials running across four continents, the next chapter of weight medicine is being written in something far less dramatic than a syringe. It is being written in a tablet — the kind you take with a glass of water, in the morning, between toast and the second cup of coffee.

If oral GLP1 medications do what their developers believe they can, the so-called Skinny Jab era may come to look like the awkward first act of something much larger. The pen, in a few years, may feel as dated as the daily insulin syringe felt after the first long-acting analogues arrived. The pill is coming. The question is what kind of world it will arrive in.

The quick answer

Why injections won the first round

GLP1 itself is a peptide — a short chain of amino acids the small intestine releases after meals. Peptides have an unfortunate habit, from a pharmaceutical point of view: they fall apart in the stomach. The acidic environment of the gut, plus the enzymes the body uses to disassemble dietary protein, treat any swallowed peptide drug as just another piece of food. By the time it reaches the bloodstream, very little of the active molecule remains.

The injection sidesteps that problem entirely. A weekly subcutaneous dose of semaglutide or tirzepatide drips slowly into circulation, intact, for seven days. That elegant solution is the reason the modern GLP1 era began as a needle story. It is also the reason many people who could benefit from the medications have, until now, decided not to start.

Surveys of patients who decline GLP1 therapy consistently surface the same handful of reasons: discomfort with self-injection, a fear of needles dating back to childhood, the logistics of refrigeration, the visibility of pens at airport security, and the simple, stubborn psychological barrier of having to puncture one's own skin once a week. None of those reasons are trivial. Each of them is a wall that an effective oral version could remove overnight.

The bioavailability problem, and the cleverness used to solve it

Rybelsus, Novo Nordisk's first oral semaglutide, was approved in 2019 for type 2 diabetes — and it was, in its own quiet way, a small pharmaceutical miracle. The trick that made it possible is a molecule called SNAC, an absorption enhancer that briefly raises the pH around the tablet in the stomach. In that protected micro-environment, a small fraction of the semaglutide survives long enough to cross the stomach lining into the bloodstream.

'Small fraction' is doing a lot of work in that sentence. Roughly one percent of an oral semaglutide dose reaches circulation, compared with nearly all of an injection. The tablet compensates by being much larger — milligrams of drug rather than micrograms — and by demanding strict conditions: an empty stomach, a small sip of water, and a thirty-minute wait before anything else passes the lips. Patients who follow the instructions get a real, measurable effect. Patients who do not, often get nothing.

For diabetes care, where the dose is modest, that compromise has been workable. For weight management, where the effective dose is several times higher, the picture is more delicate. Novo's late-stage trials of high-dose oral semaglutide for obesity — published in 2024 and 2025 — have shown weight loss approaching what Wegovy injections produce, but only when the food-and-water protocol is followed carefully. The pill works. It simply asks something of the user that the pen does not.

Why Eli Lilly's orforglipron changes the conversation

Eli Lilly took a different route. Rather than trying to smuggle a fragile peptide through the gut, the company developed a small molecule — a non-peptide GLP1 receptor agonist called orforglipron — that the digestive system does not recognise as protein at all. The molecule is small enough and stable enough to survive the journey, absorb predictably, and reach the bloodstream without the choreography of an empty stomach.

If the late-stage trial data continues to hold, orforglipron may become the first GLP1 medication that fits cleanly into an ordinary morning routine: a tablet, with food or without, at whatever time happens to be convenient. That single feature, more than any specific weight-loss percentage, is what has analysts at every major pharmaceutical bank rewriting their forecasts.

A medication that requires no needles, no refrigeration, and no special timing is no longer a treatment. It is a habit. And habits scale in ways treatments cannot.

Eli Lilly is also working on a second oral candidate, retatrutide-class compounds in tablet form, and on combinations targeting GLP1 alongside GIP and glucagon. Novo Nordisk, meanwhile, is pursuing higher-dose oral semaglutide formulations and reportedly investigating its own small-molecule alternatives. The two companies that defined the injectable era are now racing each other to define the oral one.

How an oral GLP1 actually works inside the body

The biology, once the drug reaches the bloodstream, is essentially the same as the injection. GLP1 receptors are distributed across the pancreas, the stomach lining, and several appetite-regulating regions of the brain. Activating those receptors slows gastric emptying, stabilises insulin release, and turns down the volume on the reward circuitry that drives food cravings. The route of delivery does not change the biological story; it changes who is willing to participate in it.

In practical terms, users of an effective oral GLP1 can expect the same broad pattern that injection users describe — smaller portions feeling satisfying, ultra-processed snacks losing their pull first, the slow fading of what has come to be called food noise. The intensity may differ slightly depending on dose and absorption, but the experience belongs to the same family.

What GLP1 actually feels like in the first weeks →

Convenience versus effectiveness — the trade-off nobody talks about

In the trials so far, high-dose oral semaglutide produces weight loss in the range of twelve to fifteen percent of body weight over roughly a year — slightly below the seventeen-or-so percent commonly reported for injectable Wegovy at the highest dose. Orforglipron's late-stage results are still being finalised, but early readouts suggest somewhere in a similar range, possibly higher in subgroups.

The pure pharmacology argument, then, still favours the injection by a small margin. The real-world argument may not. A medication that ten million additional people are willing to take, and able to take consistently, will reshape population health in a way that a slightly more potent medication taken by a much smaller group cannot. Adherence is itself a kind of efficacy. The pen is more potent in the lab; the pill may be more potent in the world.

What this might mean for cost and insurance

Injectable GLP1 medications remain expensive, with US list prices well above a thousand dollars a month. Several factors keep prices high: the complexity of biologic manufacturing, the cost of the prefilled pen device, cold-chain logistics, and the simple economics of patent-protected demand outstripping supply. Oral medications change every line of that equation. Tablets are cheaper to make, cheaper to ship, easier to store, and far easier to scale globally.

That does not automatically mean the consumer price will fall to the level of, say, a statin. In the short term, both Novo and Lilly have every commercial incentive to price oral GLP1s as premium products. Over the medium term, generic competition on small-molecule candidates like orforglipron — and on oral semaglutide once exclusivity erodes — could shift weight-loss medication into the same affordable bracket as today's blood-pressure and cholesterol drugs. That is not a small change. It is the difference between a luxury and a category of public health.

The global expansion problem the pill could solve

Most of the conversation around GLP1 medications happens in a handful of wealthy markets. The injection has, so far, been a North American, Western European, and Gulf phenomenon, with Brazil, Australia, and parts of East Asia growing quickly. Most of the world has not been part of the story at all. The barriers are not biological. They are logistical: cold chains, pen distribution, prescriber familiarity, and the cost of a device-based therapy in countries where the entire health budget per capita is a fraction of one month's Wegovy.

A daily pill, shelf-stable at room temperature, manufactured in tablet plants that already exist all over the world, removes most of those barriers in a single stroke. If pricing follows, the next decade of GLP1 history will probably not be written in Beverly Hills or Mayfair. It will be written in São Paulo, Lagos, Jakarta, and Mumbai — in cities where the global obesity story is unfolding much faster than the medication has so far been able to follow.

From Skinny Jabs to Skinny Pens to Skinny Pills

The language of the era keeps shifting in real time. A few years ago, the cultural shorthand was Skinny Jabs — a phrase that captured both the medication and the very specific image of a celebrity self-injecting in a hotel bathroom. Then it softened into Skinny Pens, gentler and more domestic. The next term is already forming in the corners of the internet: the Skinny Pill, or simply 'the pill,' said with the same casual specificity that 'the pill' has carried for contraception for sixty years.

That linguistic drift matters. When a medication acquires an everyday name, it begins to behave like an everyday object. Hollywood Shots became a meme because they were unusual; daily pills, by their nature, resist memeification. They are too ordinary, too quiet, too embedded in the morning routine. If oral GLP1s become culturally invisible in the way statins did, the social meaning of being on one will quietly evaporate — and that, more than any biology, may be what changes the era.

Why GLP1 culture is shifting faster than the science →

Behavioural impact: what changes when the ritual changes

There is a small but real psychological difference between injecting once a week and swallowing a pill every morning. Weekly injection users often describe the act as a kind of recommitment — a quiet seven-day ritual that anchors the experience and reminds them what they are doing. A daily tablet has the opposite quality. It disappears into the background of life. There is no weekly pause, no moment of intention, no needle to focus the mind.

For most users, this is a clear win. The treatment that requires less of you tends to be the treatment you stay on. For a smaller group, the loss of ritual may turn out to matter — particularly for those who used the weekly moment as a check-in with their own progress. The likely answer is that good tracking tools become more important, not less, as the medication itself becomes invisible. When the drug stops asking for your attention, something else has to provide the rhythm.

Open GLP1 Journal →

Appetite, food noise, and the question of intensity

Users moving from injection to pill — once that becomes a real option — will mostly notice the differences in side effects and convenience, not in the core appetite effect. Food noise quiets in much the same way. Portion sizes shrink. Ultra-processed cravings fade first. The relationship with sweet foods, in particular, often softens within weeks.

There is some early evidence that the steadier blood levels of a daily oral dose may produce a smoother day-to-day experience than the peak-and-trough curve of a weekly injection, particularly around nausea. Whether that translates into meaningfully better adherence is one of the open questions the next two years of real-world data will answer.

The risks of a much larger user base

Every story about a more accessible medication is also a story about the consequences of that accessibility. A daily oral GLP1, taken by tens of millions more people than injections ever reached, will surface long-term safety questions faster than any previous weight-loss drug. The biology is well-studied — semaglutide and tirzepatide have been in human use for years — but rare effects, drug interactions, and long-tail outcomes only become fully visible at population scale.

There is also a more subtle risk: the gradual normalisation of pharmaceutical appetite suppression in people for whom the medication is not clinically indicated. Pills are easier to share, easier to acquire informally, and easier to take without medical oversight than injections ever were. The same convenience that solves the access problem creates a new misuse problem. Both will need to be managed honestly, by prescribers and platforms alike.

The business war between Novo Nordisk and Eli Lilly

Behind the editorial story is a corporate one. Novo Nordisk, the century-old Danish company that turned semaglutide into the highest-grossing drug in pharmaceutical history, is defending a category it largely created. Eli Lilly, the American giant whose tirzepatide products have already outperformed Wegovy on raw weight-loss numbers in head-to-head trials, is pushing aggressively into oral territory in part because the small-molecule chemistry plays to its own historical strengths.

The two companies between them now account for a meaningful share of the entire global pharmaceutical market by valuation. Their oral GLP1 programmes are not a side project. They are the central strategic move of the next decade — and the outcome will decide which company defines obesity medicine for a generation. Smaller players, including Pfizer, Roche, and Amgen, are circling with their own oral and combination candidates, but the headline race remains Novo versus Lilly.

Why this matters beyond weight loss

The most quietly significant thing about the oral GLP1 wave may be how it reshapes the broader pipeline of metabolic and behavioural medicine. GLP1 receptor activity is already being studied for alcohol use disorder, nicotine dependence, opioid craving, Parkinson's disease, Alzheimer's, polycystic ovary syndrome, and several inflammatory conditions. A tablet form removes the device barrier from every one of those potential indications.

If oral GLP1s perform anywhere close to their injectable counterparts, the next generation of obesity research will likely run on tablets, the next generation of addiction research will likely run on tablets, and the next generation of cognitive-decline research will likely run on tablets. The needle, in retrospect, may be remembered as the scaffolding the field used while the chemistry caught up.

Frequently asked questions

Short answers to the questions readers most often ask about the coming oral GLP1 wave. Full clinical decisions, as always, belong with a licensed prescriber.

What to watch over the next two years

The headlines worth paying attention to are not the price-target updates from investment banks. They are the regulatory filings, the head-to-head trial readouts, and the first real-world pharmacy data from the markets where oral GLP1s launch first. Watch for the FDA and EMA decisions on high-dose oral semaglutide for weight management. Watch for orforglipron's full Phase 3 obesity data. Watch for the first national health systems outside the United States to add a daily GLP1 pill to their reimbursed formularies. Each of those moments will move the era forward in a way that none of the speculation does.

And, quietly, watch the language. The first time a major newspaper headline drops the word 'injection' from a story about Wegovy or its successors, the era will have turned. It will not be a press release. It will be a sentence.

A calmer chapter, written in tablets

The first phase of the GLP1 era was defined by the drama of the needle — by celebrity rumours, viral before-and-afters, and a slightly anxious cultural conversation about who was on the medication and who was not. The next phase is likely to be quieter. A daily pill is, by its nature, a less interesting object than a weekly pen. Less photogenic. Less narratable. More embedded in ordinary life.

That ordinariness is exactly what makes the oral GLP1 wave significant. The most consequential medications in history — birth control, statins, antidepressants, antihypertensives — are the ones that disappeared into morning routines. If Novo Nordisk and Eli Lilly succeed at what they are quietly building, the GLP1 story is about to disappear into a glass of water.

The medicine will still be doing extraordinary work. It will simply, finally, stop looking like an event.

Continue reading — what GLP1 is, in plain English →